GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » Cyclically Adjusted Revenue per Share

IRIDEX (IRIDEX) Cyclically Adjusted Revenue per Share : $4.30 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IRIDEX Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

IRIDEX's adjusted revenue per share for the three months ended in Dec. 2023 was $0.767. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.30 for the trailing ten years ended in Dec. 2023.

During the past 12 months, IRIDEX's average Cyclically Adjusted Revenue Growth Rate was -0.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of IRIDEX was 8.80% per year. The lowest was -4.90% per year. And the median was -1.50% per year.

As of today (2024-05-15), IRIDEX's current stock price is $3.08. IRIDEX's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $4.30. IRIDEX's Cyclically Adjusted PS Ratio of today is 0.72.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IRIDEX was 3.46. The lowest was 0.30. And the median was 1.45.


IRIDEX Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for IRIDEX's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Cyclically Adjusted Revenue per Share Chart

IRIDEX Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.01 3.94 4.17 4.33 4.30

IRIDEX Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.33 4.37 4.38 4.37 4.30

Competitive Comparison of IRIDEX's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, IRIDEX's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRIDEX's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where IRIDEX's Cyclically Adjusted PS Ratio falls into.



IRIDEX Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IRIDEX's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.767/129.4194*129.4194
=0.767

Current CPI (Dec. 2023) = 129.4194.

IRIDEX Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.981 99.695 1.273
201406 1.017 100.560 1.309
201409 0.987 100.428 1.272
201412 1.151 99.070 1.504
201503 1.068 99.621 1.387
201506 0.901 100.684 1.158
201509 0.972 100.392 1.253
201512 1.201 99.792 1.558
201603 1.177 100.470 1.516
201606 1.181 101.688 1.503
201609 0.966 101.861 1.227
201612 1.200 101.863 1.525
201703 0.910 102.862 1.145
201706 0.866 103.349 1.084
201709 0.939 104.136 1.167
201712 0.884 104.011 1.100
201803 0.818 105.290 1.005
201806 0.885 106.317 1.077
201809 0.949 106.507 1.153
201812 0.843 105.998 1.029
201903 0.777 107.251 0.938
201906 0.764 108.070 0.915
201909 0.775 108.329 0.926
201912 0.853 108.420 1.018
202003 0.654 108.902 0.777
202006 0.451 108.767 0.537
202009 0.634 109.815 0.747
202012 0.885 109.897 1.042
202103 0.834 111.754 0.966
202106 0.823 114.631 0.929
202109 0.838 115.734 0.937
202112 0.961 117.630 1.057
202203 0.843 121.301 0.899
202206 0.865 125.017 0.895
202209 0.915 125.227 0.946
202212 0.950 125.222 0.982
202303 0.857 127.348 0.871
202306 0.802 128.729 0.806
202309 0.792 129.860 0.789
202312 0.767 129.419 0.767

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


IRIDEX  (NAS:IRIX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

IRIDEX's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.08/4.3
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IRIDEX was 3.46. The lowest was 0.30. And the median was 1.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


IRIDEX Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of IRIDEX's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


IRIDEX (IRIDEX) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Executives
Nandini Devi director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss director C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp 10 percent owner 75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp 10 percent owner 111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous director C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda director 402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer officer: COO 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne director
Robert A Gunst director
David Bruce director, officer: President and CEO 1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum director
Romeo R Dizon other: Vice President and Controller 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043

IRIDEX (IRIDEX) Headlines